Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 200 | 2024 | 21056 | 4.580 |
Why?
|
Mastectomy, Segmental | 60 | 2023 | 964 | 3.290 |
Why?
|
Radiotherapy, Adjuvant | 35 | 2024 | 1776 | 3.140 |
Why?
|
Mastectomy | 41 | 2024 | 1847 | 2.910 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 34 | 2021 | 920 | 1.730 |
Why?
|
Neoplasm Recurrence, Local | 94 | 2024 | 9373 | 1.710 |
Why?
|
Lymph Node Excision | 22 | 2023 | 1259 | 1.430 |
Why?
|
Carcinoma in Situ | 18 | 2016 | 779 | 1.340 |
Why?
|
Carcinoma, Ductal, Breast | 20 | 2016 | 1083 | 1.200 |
Why?
|
Lymph Nodes | 20 | 2024 | 3454 | 1.160 |
Why?
|
Radiation Injuries | 12 | 2017 | 1181 | 1.110 |
Why?
|
Mammaplasty | 10 | 2024 | 1264 | 1.040 |
Why?
|
Radiotherapy, Conformal | 9 | 2014 | 533 | 1.020 |
Why?
|
Combined Modality Therapy | 97 | 2019 | 8529 | 0.910 |
Why?
|
Axilla | 22 | 2023 | 615 | 0.780 |
Why?
|
Lymphatic Metastasis | 44 | 2024 | 2887 | 0.760 |
Why?
|
Lymphatic Irradiation | 5 | 2024 | 110 | 0.720 |
Why?
|
Brachytherapy | 8 | 2017 | 1222 | 0.670 |
Why?
|
Radiation Oncology | 9 | 2017 | 569 | 0.640 |
Why?
|
Radiotherapy | 18 | 2019 | 1494 | 0.620 |
Why?
|
Dermatomyositis | 1 | 2021 | 261 | 0.590 |
Why?
|
Neoplasm Staging | 55 | 2020 | 11206 | 0.570 |
Why?
|
Aromatase Inhibitors | 4 | 2022 | 518 | 0.540 |
Why?
|
Practice Guidelines as Topic | 6 | 2018 | 7425 | 0.530 |
Why?
|
Chemotherapy, Adjuvant | 28 | 2016 | 3537 | 0.520 |
Why?
|
Patient Satisfaction | 5 | 2015 | 3475 | 0.510 |
Why?
|
Female | 218 | 2024 | 396112 | 0.490 |
Why?
|
Sentinel Lymph Node Biopsy | 8 | 2023 | 728 | 0.480 |
Why?
|
Tamoxifen | 14 | 2015 | 963 | 0.470 |
Why?
|
Bone Neoplasms | 3 | 2023 | 2567 | 0.470 |
Why?
|
Fluorouracil | 10 | 2005 | 1648 | 0.470 |
Why?
|
Radiotherapy Dosage | 23 | 2020 | 2865 | 0.450 |
Why?
|
Mastectomy, Radical | 3 | 2003 | 19 | 0.440 |
Why?
|
Humans | 243 | 2024 | 765968 | 0.420 |
Why?
|
Antineoplastic Agents, Hormonal | 9 | 2019 | 1534 | 0.400 |
Why?
|
Breast | 10 | 2023 | 1946 | 0.370 |
Why?
|
Meta-Analysis as Topic | 6 | 2022 | 1370 | 0.360 |
Why?
|
Deglutition Disorders | 1 | 2017 | 639 | 0.360 |
Why?
|
Cyclophosphamide | 9 | 2012 | 2228 | 0.350 |
Why?
|
SEER Program | 6 | 2013 | 1446 | 0.350 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 27 | 2012 | 11868 | 0.340 |
Why?
|
Mastectomy, Modified Radical | 3 | 2000 | 59 | 0.340 |
Why?
|
Wound Healing | 1 | 2021 | 2792 | 0.340 |
Why?
|
Methotrexate | 7 | 2005 | 1722 | 0.310 |
Why?
|
Mastectomy, Simple | 2 | 2007 | 23 | 0.310 |
Why?
|
Heart | 6 | 2018 | 4414 | 0.270 |
Why?
|
Randomized Controlled Trials as Topic | 18 | 2024 | 10383 | 0.270 |
Why?
|
Seroma | 1 | 2007 | 74 | 0.270 |
Why?
|
Patient Compliance | 2 | 2020 | 2692 | 0.260 |
Why?
|
Middle Aged | 112 | 2024 | 223009 | 0.260 |
Why?
|
Radiosurgery | 3 | 2023 | 1328 | 0.250 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 10 | 2013 | 5389 | 0.250 |
Why?
|
Insurance, Liability | 2 | 2017 | 100 | 0.250 |
Why?
|
Aged | 94 | 2024 | 171117 | 0.240 |
Why?
|
Antineoplastic Agents | 10 | 2018 | 13648 | 0.240 |
Why?
|
Carcinoma, Lobular | 3 | 2005 | 471 | 0.240 |
Why?
|
Heart Diseases | 2 | 2017 | 2821 | 0.230 |
Why?
|
Lymphedema | 2 | 2023 | 525 | 0.230 |
Why?
|
Nitriles | 1 | 2010 | 982 | 0.230 |
Why?
|
Treatment Outcome | 44 | 2024 | 65188 | 0.230 |
Why?
|
Triazoles | 1 | 2010 | 897 | 0.230 |
Why?
|
Lung Neoplasms | 14 | 2017 | 13451 | 0.220 |
Why?
|
Markov Chains | 4 | 2020 | 968 | 0.220 |
Why?
|
Survival Rate | 22 | 2016 | 12795 | 0.220 |
Why?
|
Doxorubicin | 6 | 2012 | 2230 | 0.220 |
Why?
|
Neoplasm Invasiveness | 13 | 2018 | 3602 | 0.220 |
Why?
|
Patient Selection | 6 | 2013 | 4255 | 0.210 |
Why?
|
Particle Accelerators | 2 | 2003 | 174 | 0.210 |
Why?
|
Estrogen Antagonists | 1 | 2003 | 150 | 0.210 |
Why?
|
Survival Analysis | 22 | 2011 | 10070 | 0.200 |
Why?
|
Follow-Up Studies | 53 | 2016 | 39193 | 0.200 |
Why?
|
Disease-Free Survival | 14 | 2012 | 6832 | 0.200 |
Why?
|
Societies, Medical | 4 | 2016 | 3956 | 0.190 |
Why?
|
Age Factors | 17 | 2020 | 18380 | 0.190 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 4 | 2017 | 1643 | 0.180 |
Why?
|
Malpractice | 2 | 2017 | 561 | 0.180 |
Why?
|
Postoperative Complications | 5 | 2019 | 15747 | 0.180 |
Why?
|
Pneumonectomy | 6 | 2013 | 1128 | 0.180 |
Why?
|
United States | 19 | 2021 | 72903 | 0.180 |
Why?
|
Medical Oncology | 3 | 2016 | 2339 | 0.170 |
Why?
|
Neoplasms, Second Primary | 7 | 2012 | 1050 | 0.170 |
Why?
|
Aged, 80 and over | 41 | 2021 | 59489 | 0.170 |
Why?
|
Adult | 88 | 2024 | 223044 | 0.170 |
Why?
|
Postoperative Care | 2 | 2003 | 1470 | 0.160 |
Why?
|
Prognosis | 36 | 2015 | 29922 | 0.160 |
Why?
|
Phyllodes Tumor | 1 | 2019 | 54 | 0.160 |
Why?
|
Mediastinum | 3 | 2017 | 271 | 0.160 |
Why?
|
Neoplasms, Multiple Primary | 6 | 2000 | 587 | 0.160 |
Why?
|
Treatment Failure | 11 | 2010 | 2652 | 0.160 |
Why?
|
Receptors, Estrogen | 8 | 2021 | 2242 | 0.160 |
Why?
|
Cost-Benefit Analysis | 6 | 2022 | 5526 | 0.160 |
Why?
|
Adenocarcinoma | 12 | 2012 | 6364 | 0.150 |
Why?
|
Pneumonia | 2 | 2009 | 2157 | 0.150 |
Why?
|
Spinal Cord Compression | 1 | 2020 | 234 | 0.150 |
Why?
|
Ontario | 1 | 2019 | 402 | 0.150 |
Why?
|
Prospective Studies | 23 | 2023 | 54802 | 0.150 |
Why?
|
United States Food and Drug Administration | 2 | 2017 | 1672 | 0.150 |
Why?
|
Antimetabolites, Antineoplastic | 2 | 1998 | 647 | 0.150 |
Why?
|
Delivery of Health Care | 1 | 2016 | 5370 | 0.140 |
Why?
|
Antidotes | 1 | 1998 | 138 | 0.140 |
Why?
|
Receptor, erbB-2 | 4 | 2023 | 2593 | 0.140 |
Why?
|
Decision Support Techniques | 4 | 2021 | 2003 | 0.140 |
Why?
|
Retrospective Studies | 43 | 2019 | 81514 | 0.140 |
Why?
|
Age of Onset | 1 | 2004 | 3344 | 0.140 |
Why?
|
Rectal Neoplasms | 6 | 1998 | 1182 | 0.140 |
Why?
|
Medical Device Recalls | 1 | 2017 | 15 | 0.140 |
Why?
|
Time Factors | 22 | 2017 | 40065 | 0.130 |
Why?
|
Heartburn | 1 | 2017 | 71 | 0.130 |
Why?
|
Dose-Response Relationship, Radiation | 3 | 2016 | 869 | 0.130 |
Why?
|
Leucovorin | 1 | 1998 | 641 | 0.130 |
Why?
|
Organs at Risk | 1 | 2018 | 352 | 0.130 |
Why?
|
Small Cell Lung Carcinoma | 2 | 2011 | 451 | 0.130 |
Why?
|
Lung | 3 | 2012 | 10033 | 0.130 |
Why?
|
Clinical Trials as Topic | 10 | 2019 | 8041 | 0.130 |
Why?
|
Equipment Safety | 1 | 2017 | 250 | 0.130 |
Why?
|
Myocardial Ischemia | 1 | 2006 | 2128 | 0.130 |
Why?
|
Standard of Care | 1 | 2020 | 567 | 0.130 |
Why?
|
Decision Making | 4 | 2021 | 3965 | 0.120 |
Why?
|
Product Surveillance, Postmarketing | 2 | 2017 | 464 | 0.120 |
Why?
|
Electrons | 4 | 2006 | 265 | 0.120 |
Why?
|
Rheumatic Diseases | 1 | 2001 | 622 | 0.120 |
Why?
|
Neoplasms, Radiation-Induced | 2 | 2001 | 540 | 0.120 |
Why?
|
Radiotherapy, High-Energy | 4 | 1992 | 226 | 0.120 |
Why?
|
Neoplasm Metastasis | 9 | 2009 | 4893 | 0.120 |
Why?
|
Adenocarcinoma, Mucinous | 7 | 2006 | 521 | 0.120 |
Why?
|
Carcinoma | 3 | 1998 | 2312 | 0.120 |
Why?
|
China | 1 | 2020 | 2385 | 0.110 |
Why?
|
Equipment Failure Analysis | 1 | 2017 | 834 | 0.110 |
Why?
|
Radiotherapy, Intensity-Modulated | 1 | 2020 | 784 | 0.110 |
Why?
|
Microsurgery | 1 | 2019 | 795 | 0.110 |
Why?
|
Carcinoma, Large Cell | 2 | 2011 | 114 | 0.110 |
Why?
|
Evidence-Based Medicine | 2 | 2010 | 3685 | 0.100 |
Why?
|
Photons | 2 | 2014 | 572 | 0.100 |
Why?
|
Chi-Square Distribution | 3 | 2017 | 3432 | 0.100 |
Why?
|
Bayes Theorem | 1 | 2020 | 2354 | 0.100 |
Why?
|
Medical Errors | 2 | 2017 | 1260 | 0.100 |
Why?
|
Salvage Therapy | 7 | 2019 | 1272 | 0.100 |
Why?
|
Life Expectancy | 1 | 2018 | 1247 | 0.090 |
Why?
|
Incidence | 12 | 2019 | 21480 | 0.090 |
Why?
|
Proton Pump Inhibitors | 1 | 2017 | 553 | 0.090 |
Why?
|
Adenocarcinoma, Bronchiolo-Alveolar | 2 | 2009 | 83 | 0.090 |
Why?
|
Pain | 2 | 2023 | 5077 | 0.090 |
Why?
|
Paget's Disease, Mammary | 2 | 2003 | 18 | 0.090 |
Why?
|
Palliative Care | 2 | 2023 | 3645 | 0.090 |
Why?
|
Actuarial Analysis | 8 | 1996 | 366 | 0.090 |
Why?
|
Posture | 2 | 2006 | 954 | 0.090 |
Why?
|
Risk Factors | 23 | 2018 | 74840 | 0.080 |
Why?
|
Databases, Factual | 4 | 2020 | 8067 | 0.080 |
Why?
|
Esthetics | 6 | 2006 | 326 | 0.080 |
Why?
|
Radiation Dosage | 3 | 2009 | 1944 | 0.080 |
Why?
|
Risk Assessment | 7 | 2016 | 24282 | 0.080 |
Why?
|
Fractures, Bone | 1 | 2020 | 2041 | 0.080 |
Why?
|
Tumor Burden | 4 | 2018 | 1885 | 0.070 |
Why?
|
Diabetes Complications | 2 | 2013 | 1316 | 0.070 |
Why?
|
Lymphoma | 2 | 2017 | 1897 | 0.070 |
Why?
|
Esophageal Neoplasms | 2 | 1995 | 1661 | 0.070 |
Why?
|
Lymphatic System | 1 | 1989 | 250 | 0.070 |
Why?
|
Gene Expression Profiling | 2 | 2016 | 9525 | 0.070 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2011 | 341 | 0.070 |
Why?
|
Quality of Life | 2 | 2024 | 13462 | 0.060 |
Why?
|
Software | 2 | 2017 | 4462 | 0.060 |
Why?
|
Death Certificates | 1 | 2006 | 170 | 0.060 |
Why?
|
Barrett Esophagus | 1 | 2008 | 494 | 0.060 |
Why?
|
Sigmoid Neoplasms | 3 | 1989 | 54 | 0.060 |
Why?
|
Carcinoma, Medullary | 1 | 2004 | 114 | 0.050 |
Why?
|
Manuals as Topic | 1 | 2003 | 100 | 0.050 |
Why?
|
Proportional Hazards Models | 7 | 2015 | 12509 | 0.050 |
Why?
|
Drug Therapy | 1 | 2006 | 504 | 0.050 |
Why?
|
Multivariate Analysis | 8 | 2015 | 12056 | 0.050 |
Why?
|
Case-Control Studies | 3 | 2010 | 22223 | 0.050 |
Why?
|
Quality-Adjusted Life Years | 2 | 2020 | 1737 | 0.050 |
Why?
|
Advisory Committees | 2 | 2006 | 796 | 0.050 |
Why?
|
Tattooing | 1 | 2003 | 56 | 0.050 |
Why?
|
Biopsy | 6 | 2009 | 6763 | 0.050 |
Why?
|
Linear Models | 3 | 2017 | 5876 | 0.050 |
Why?
|
Multicenter Studies as Topic | 2 | 2000 | 1731 | 0.050 |
Why?
|
Male | 27 | 2021 | 363698 | 0.050 |
Why?
|
Mathematics | 1 | 2003 | 696 | 0.050 |
Why?
|
Arm | 3 | 1999 | 589 | 0.050 |
Why?
|
Cardiomyopathies | 1 | 1994 | 2067 | 0.050 |
Why?
|
Surgical Flaps | 1 | 2010 | 1677 | 0.050 |
Why?
|
Scattering, Radiation | 1 | 2003 | 482 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 2 | 2015 | 6499 | 0.050 |
Why?
|
Statistics, Nonparametric | 2 | 2017 | 2844 | 0.050 |
Why?
|
Mesothelioma | 3 | 1997 | 771 | 0.050 |
Why?
|
Telangiectasis | 2 | 2014 | 77 | 0.040 |
Why?
|
Breast Implants | 1 | 2024 | 411 | 0.040 |
Why?
|
Dactinomycin | 1 | 2001 | 304 | 0.040 |
Why?
|
Edema | 3 | 1999 | 760 | 0.040 |
Why?
|
Skin | 1 | 2014 | 4489 | 0.040 |
Why?
|
Career Choice | 1 | 2007 | 769 | 0.040 |
Why?
|
Laryngeal Neoplasms | 1 | 1984 | 512 | 0.040 |
Why?
|
Prevalence | 1 | 2017 | 15842 | 0.040 |
Why?
|
Teaching | 1 | 2007 | 1169 | 0.040 |
Why?
|
Logistic Models | 4 | 2017 | 13266 | 0.040 |
Why?
|
Hormones | 1 | 2022 | 863 | 0.040 |
Why?
|
Fluoroscopy | 1 | 2003 | 947 | 0.040 |
Why?
|
Genes, erbB-2 | 1 | 2019 | 160 | 0.040 |
Why?
|
Immunohistochemistry | 2 | 2015 | 11022 | 0.040 |
Why?
|
Preoperative Care | 2 | 1998 | 2267 | 0.040 |
Why?
|
Faculty, Medical | 1 | 2007 | 1219 | 0.040 |
Why?
|
Rectum | 2 | 1997 | 896 | 0.040 |
Why?
|
Neoadjuvant Therapy | 3 | 2012 | 2895 | 0.040 |
Why?
|
Risk | 4 | 2019 | 9591 | 0.040 |
Why?
|
Mammography | 5 | 2009 | 2423 | 0.040 |
Why?
|
Relative Biological Effectiveness | 1 | 2019 | 299 | 0.040 |
Why?
|
Recurrence | 4 | 2010 | 8501 | 0.040 |
Why?
|
Product Recalls and Withdrawals | 1 | 2017 | 7 | 0.030 |
Why?
|
Interferon-alpha | 1 | 2001 | 910 | 0.030 |
Why?
|
Technology, Radiologic | 1 | 2017 | 158 | 0.030 |
Why?
|
Radiation Tolerance | 1 | 1998 | 475 | 0.030 |
Why?
|
Models, Economic | 1 | 2020 | 716 | 0.030 |
Why?
|
Mediastinal Neoplasms | 2 | 2010 | 403 | 0.030 |
Why?
|
Contraceptives, Oral, Hormonal | 1 | 2016 | 187 | 0.030 |
Why?
|
Drug Administration Schedule | 1 | 2003 | 4850 | 0.030 |
Why?
|
Device Approval | 1 | 2017 | 164 | 0.030 |
Why?
|
Epithelial Cells | 1 | 2007 | 3681 | 0.030 |
Why?
|
Equipment Design | 1 | 2003 | 3481 | 0.030 |
Why?
|
Mass Screening | 2 | 2009 | 5446 | 0.030 |
Why?
|
Etanidazole | 1 | 1994 | 22 | 0.030 |
Why?
|
Cosmetics | 1 | 1996 | 102 | 0.030 |
Why?
|
Phantoms, Imaging | 1 | 2003 | 2475 | 0.030 |
Why?
|
Equipment and Supplies | 1 | 2017 | 273 | 0.030 |
Why?
|
Leukemia, Radiation-Induced | 1 | 1994 | 36 | 0.030 |
Why?
|
Radiodermatitis | 1 | 2014 | 58 | 0.030 |
Why?
|
Fat Necrosis | 1 | 2014 | 59 | 0.030 |
Why?
|
Postmenopause | 1 | 2003 | 2515 | 0.030 |
Why?
|
Thiophenes | 1 | 1998 | 569 | 0.030 |
Why?
|
Forecasting | 2 | 2012 | 2936 | 0.030 |
Why?
|
Probability | 1 | 2019 | 2475 | 0.030 |
Why?
|
Primary Ovarian Insufficiency | 1 | 1994 | 104 | 0.030 |
Why?
|
Matched-Pair Analysis | 1 | 2013 | 284 | 0.030 |
Why?
|
Medicare | 2 | 2021 | 6823 | 0.020 |
Why?
|
Skin Pigmentation | 1 | 2014 | 279 | 0.020 |
Why?
|
Pleural Neoplasms | 1 | 1997 | 581 | 0.020 |
Why?
|
Quinazolines | 1 | 1998 | 1364 | 0.020 |
Why?
|
Colonic Neoplasms | 3 | 1988 | 2531 | 0.020 |
Why?
|
Colorectal Neoplasms | 2 | 2002 | 6942 | 0.020 |
Why?
|
Neoplasm, Residual | 2 | 2012 | 1009 | 0.020 |
Why?
|
Registries | 2 | 2006 | 8297 | 0.020 |
Why?
|
Peritoneal Neoplasms | 2 | 1988 | 703 | 0.020 |
Why?
|
Hormone Replacement Therapy | 1 | 2016 | 753 | 0.020 |
Why?
|
Comorbidity | 1 | 2005 | 10563 | 0.020 |
Why?
|
Radioisotope Teletherapy | 1 | 1989 | 15 | 0.020 |
Why?
|
Diagnosis-Related Groups | 1 | 1992 | 445 | 0.020 |
Why?
|
Sex Distribution | 1 | 2015 | 2263 | 0.020 |
Why?
|
Feasibility Studies | 3 | 2014 | 5302 | 0.020 |
Why?
|
Cricetinae | 1 | 1993 | 2411 | 0.020 |
Why?
|
Palpation | 1 | 2009 | 166 | 0.020 |
Why?
|
Vinblastine | 1 | 2010 | 483 | 0.020 |
Why?
|
Patient Education as Topic | 1 | 2019 | 2334 | 0.020 |
Why?
|
Clavicle | 1 | 1991 | 224 | 0.020 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2009 | 4044 | 0.020 |
Why?
|
Carcinoma, Adenosquamous | 1 | 2009 | 66 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2002 | 7838 | 0.020 |
Why?
|
Technetium Tc 99m Sulfur Colloid | 1 | 1988 | 63 | 0.020 |
Why?
|
Peripheral Nervous System Diseases | 1 | 1994 | 712 | 0.020 |
Why?
|
Cisplatin | 2 | 2010 | 1658 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 3 | 2011 | 36532 | 0.020 |
Why?
|
Qualitative Research | 1 | 2019 | 3139 | 0.020 |
Why?
|
Sarcoma | 2 | 2002 | 1802 | 0.020 |
Why?
|
Enzyme Inhibitors | 1 | 1998 | 3715 | 0.020 |
Why?
|
Genomics | 1 | 2023 | 5929 | 0.020 |
Why?
|
Colon, Sigmoid | 1 | 1988 | 124 | 0.020 |
Why?
|
Europe | 2 | 1996 | 3423 | 0.020 |
Why?
|
Necrosis | 2 | 1992 | 1617 | 0.020 |
Why?
|
Ultrasonography, Mammary | 1 | 2009 | 241 | 0.020 |
Why?
|
Evaluation Studies as Topic | 1 | 1989 | 1600 | 0.020 |
Why?
|
Carboplatin | 1 | 2010 | 789 | 0.020 |
Why?
|
Receptors, Progesterone | 1 | 2012 | 1153 | 0.020 |
Why?
|
Phosphorus Radioisotopes | 1 | 1987 | 100 | 0.020 |
Why?
|
Radionuclide Imaging | 2 | 1988 | 1978 | 0.020 |
Why?
|
Medicine | 1 | 2015 | 942 | 0.020 |
Why?
|
Cohort Studies | 6 | 2011 | 41649 | 0.020 |
Why?
|
Esophagoscopy | 1 | 2008 | 398 | 0.020 |
Why?
|
Internship and Residency | 1 | 2007 | 5946 | 0.020 |
Why?
|
Propensity Score | 1 | 2013 | 1968 | 0.020 |
Why?
|
Nervous System Diseases | 1 | 1995 | 1660 | 0.010 |
Why?
|
Poisson Distribution | 1 | 2006 | 508 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2003 | 20124 | 0.010 |
Why?
|
Specimen Handling | 1 | 2009 | 704 | 0.010 |
Why?
|
Craniopharyngioma | 1 | 1987 | 276 | 0.010 |
Why?
|
Career Mobility | 1 | 2007 | 259 | 0.010 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2019 | 4058 | 0.010 |
Why?
|
Endometrial Neoplasms | 1 | 1994 | 1378 | 0.010 |
Why?
|
Epithelium | 1 | 2008 | 1599 | 0.010 |
Why?
|
Boston | 1 | 2016 | 9338 | 0.010 |
Why?
|
Regression Analysis | 3 | 2000 | 6322 | 0.010 |
Why?
|
Neovascularization, Pathologic | 1 | 1994 | 2631 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 3 | 2003 | 20659 | 0.010 |
Why?
|
Paclitaxel | 1 | 2010 | 1728 | 0.010 |
Why?
|
Methods | 2 | 1997 | 1052 | 0.010 |
Why?
|
Esophagus | 1 | 2008 | 1037 | 0.010 |
Why?
|
Surgery, Plastic | 1 | 1989 | 651 | 0.010 |
Why?
|
Glottis | 1 | 1984 | 212 | 0.010 |
Why?
|
Blood Vessels | 1 | 1988 | 1113 | 0.010 |
Why?
|
Anxiety | 1 | 2016 | 4671 | 0.010 |
Why?
|
Mentors | 1 | 2007 | 671 | 0.010 |
Why?
|
Biopsy, Needle | 1 | 2005 | 1628 | 0.010 |
Why?
|
Vocal Cords | 1 | 1984 | 520 | 0.010 |
Why?
|
Length of Stay | 1 | 2013 | 6485 | 0.010 |
Why?
|
Computer Simulation | 1 | 2013 | 6255 | 0.010 |
Why?
|
Analysis of Variance | 2 | 2000 | 6203 | 0.010 |
Why?
|
International Cooperation | 1 | 2005 | 1432 | 0.010 |
Why?
|
Pituitary Neoplasms | 1 | 1987 | 1321 | 0.010 |
Why?
|
Thymidylate Synthase | 1 | 1998 | 73 | 0.010 |
Why?
|
Neoplasms | 2 | 2017 | 22340 | 0.010 |
Why?
|
Skin Neoplasms | 1 | 1998 | 5849 | 0.010 |
Why?
|
HT29 Cells | 1 | 1998 | 187 | 0.010 |
Why?
|
Carcinoma, Lewis Lung | 1 | 1998 | 106 | 0.010 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 1994 | 3646 | 0.010 |
Why?
|
Early Detection of Cancer | 1 | 2012 | 3236 | 0.010 |
Why?
|
Myocardial Infarction | 1 | 1998 | 11499 | 0.010 |
Why?
|
Health Care Costs | 1 | 2009 | 3242 | 0.010 |
Why?
|
Pilot Projects | 2 | 1999 | 8733 | 0.010 |
Why?
|
Abdominal Neoplasms | 1 | 1997 | 284 | 0.010 |
Why?
|
Neoplasm Transplantation | 1 | 1998 | 2014 | 0.010 |
Why?
|
Thoracic Neoplasms | 1 | 1997 | 267 | 0.010 |
Why?
|
Heart Failure | 1 | 1998 | 11840 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2015 | 26318 | 0.010 |
Why?
|
Drug Interactions | 1 | 1998 | 1417 | 0.010 |
Why?
|
Body Mass Index | 1 | 2011 | 13039 | 0.010 |
Why?
|
Young Adult | 2 | 2011 | 59889 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2009 | 8611 | 0.010 |
Why?
|
Ovarian Neoplasms | 2 | 2002 | 4900 | 0.010 |
Why?
|
Diabetes Mellitus | 1 | 2011 | 5891 | 0.010 |
Why?
|
Ovariectomy | 1 | 1994 | 611 | 0.010 |
Why?
|
Muscle, Skeletal | 1 | 2006 | 4958 | 0.010 |
Why?
|
Survivors | 1 | 2002 | 2372 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 1998 | 6113 | 0.010 |
Why?
|
Rib Fractures | 1 | 1992 | 124 | 0.010 |
Why?
|
Family Health | 1 | 1995 | 1253 | 0.010 |
Why?
|
Pericarditis | 1 | 1992 | 137 | 0.010 |
Why?
|
Transplantation, Heterologous | 1 | 1998 | 2394 | 0.010 |
Why?
|
Brachial Plexus | 1 | 1992 | 174 | 0.010 |
Why?
|
Vincristine | 1 | 1991 | 1039 | 0.000 |
Why?
|
Cell Survival | 1 | 1998 | 5747 | 0.000 |
Why?
|
Odds Ratio | 1 | 2000 | 9649 | 0.000 |
Why?
|
Neck | 1 | 1992 | 733 | 0.000 |
Why?
|
Prednisone | 1 | 1991 | 1565 | 0.000 |
Why?
|
Dose-Response Relationship, Drug | 1 | 1998 | 10729 | 0.000 |
Why?
|
Dysgerminoma | 1 | 1986 | 66 | 0.000 |
Why?
|
Animals | 2 | 1998 | 168764 | 0.000 |
Why?
|
Injections, Intravenous | 1 | 1987 | 1377 | 0.000 |
Why?
|
Head and Neck Neoplasms | 1 | 1998 | 2921 | 0.000 |
Why?
|
Predictive Value of Tests | 2 | 1990 | 15398 | 0.000 |
Why?
|
Melanoma | 1 | 2002 | 5719 | 0.000 |
Why?
|
Adolescent | 2 | 2009 | 88835 | 0.000 |
Why?
|
Random Allocation | 1 | 1987 | 2395 | 0.000 |
Why?
|
Prostheses and Implants | 1 | 1989 | 1273 | 0.000 |
Why?
|
Hand | 1 | 1987 | 909 | 0.000 |
Why?
|
Statistics as Topic | 1 | 1987 | 2352 | 0.000 |
Why?
|
Testicular Neoplasms | 1 | 1986 | 786 | 0.000 |
Why?
|
Mice, Inbred C57BL | 1 | 1998 | 22332 | 0.000 |
Why?
|
Emergencies | 1 | 1986 | 1223 | 0.000 |
Why?
|
Physical Examination | 1 | 1985 | 1266 | 0.000 |
Why?
|
Disease Progression | 1 | 1995 | 13632 | 0.000 |
Why?
|
Reoperation | 1 | 1987 | 4294 | 0.000 |
Why?
|
Radiography | 1 | 1987 | 6919 | 0.000 |
Why?
|
Mice | 1 | 1998 | 81819 | 0.000 |
Why?
|
Image Processing, Computer-Assisted | 1 | 1988 | 8923 | 0.000 |
Why?
|
Diagnosis, Differential | 1 | 1986 | 12976 | 0.000 |
Why?
|
Child, Preschool | 1 | 1986 | 42500 | 0.000 |
Why?
|
Child | 1 | 1986 | 80564 | 0.000 |
Why?
|